Literature DB >> 22551926

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids.

Francis J Gilchrist1, A Kevin Webb, Rowland J Bright-Thomas, Andrew M Jones.   

Abstract

Burkholderia cepacia complex (BCC) is a group of 17 closely related bacterial species that can cause pulmonary infection in patients with cystic fibrosis (CF). The clinical manifestations of BCC infection are varied but can include cepacia syndrome, which is a rapidly progressing necrotising pneumonia with an almost universally fatal outcome. We report the case of a 38 year old man, known to have chronic infection with the ET12 strain of Burkholderia cenocepacia who developed cepacia syndrome 26 years after initial infection. Aggressive treatment with a combination of 4 intravenous antibiotics, oral corticosteroids and cyclosporin brought about clinical, radiological and biochemical resolution of his cepacia syndrome. This case highlights the possible role of cyclosporin in the treatment of cepacia syndrome.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551926     DOI: 10.1016/j.jcf.2012.04.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  9 in total

1.  In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Anina Ratjen; Yvonne Yau; Jillian Wettlaufer; Larissa Matukas; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

2.  Refractory Burkholderia cepacia bacteraemia from a consolidation pneumonia lasting more than 7 weeks, successfully treated with systemic antibiotics and nebulised meropenem.

Authors:  Bryan Albert Lim; Adelaine Lopez; Joseph Adrian Buensalido
Journal:  BMJ Case Rep       Date:  2019-08-02

3.  Cepacia Syndrome in a Non-Cystic Fibrosis Patient.

Authors:  Naomi Hauser; Jose Orsini
Journal:  Case Rep Infect Dis       Date:  2015-08-18

4.  Garlic revisited: antimicrobial activity of allicin-containing garlic extracts against Burkholderia cepacia complex.

Authors:  Daynea Wallock-Richards; Catherine J Doherty; Lynsey Doherty; David J Clarke; Marc Place; John R W Govan; Dominic J Campopiano
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 5.  Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches.

Authors:  Viola C Scoffone; Laurent R Chiarelli; Gabriele Trespidi; Massimo Mentasti; Giovanna Riccardi; Silvia Buroni
Journal:  Front Microbiol       Date:  2017-08-22       Impact factor: 5.640

6.  Loss of O-Linked Protein Glycosylation in Burkholderia cenocepacia Impairs Biofilm Formation and Siderophore Activity and Alters Transcriptional Regulators.

Authors:  Cameron C Oppy; Leila Jebeli; Miku Kuba; Clare V Oates; Richard Strugnell; Laura E Edgington-Mitchell; Miguel A Valvano; Elizabeth L Hartland; Hayley J Newton; Nichollas E Scott
Journal:  mSphere       Date:  2019-11-13       Impact factor: 4.389

7.  SARS-CoV-2 and Burkholderia cenocepacia infection in a patient with Cystic Fibrosis: An unfavourable conjunction?

Authors:  C Olcese; R Casciaro; D Pirlo; C Debbia; E Castagnola; F Cresta; C Castellani
Journal:  J Cyst Fibros       Date:  2021-04-08       Impact factor: 5.482

Review 8.  Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections.

Authors:  Sílvia A Sousa; António M M Seixas; Joana M M Marques; Jorge H Leitão
Journal:  Vaccines (Basel)       Date:  2021-06-18

9.  New Auranofin Analogs with Antibacterial Properties against Burkholderia Clinical Isolates.

Authors:  Dustin Maydaniuk; Bin Wu; Dang Truong; Sajani H Liyanage; Andrew M Hogan; Zhong Ling Yap; Mingdi Yan; Silvia T Cardona
Journal:  Antibiotics (Basel)       Date:  2021-11-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.